Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate‐P®)
Authors:
- 6 January 2004
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 10 (1) , 42-51
Abstract
Summary. von Willebrand disease (VWD) is characterized by insufficient von Willebrand factor (VWF) activity. It has been proposed that VWF:ristocetin cofactor (VWF:RCo) activity may be useful in evaluating the response to VWD treatment in patients who require replacement therapy. This prospective, open‐label, non‐randomized study evaluated the safety and efficacy of a factor VIII (FVIII)/VWF concentrate (Humate‐P®) used in treatment regimens based on VWF:RCo activity in subjects with VWD in situations requiring urgent and necessary surgery. This article summarizes the results for 39 subjects with 42 evaluable surgical treatment events, 100% of which were rated as excellent/good for overall efficacy (achievement of haemostasis). The median loading dose based upon VWF:RCo activity was 82.3 international units/kilogram (IU kg−1; range 32.5–216.8 IU kg−1), and the median maintenance dose per infusion was 52.8 IU kg−1 (range 24.2–196.5 IU kg−1) for a median of 3 days (range 1–50 days). The median number of infusions per event was 6 (range 1–67 infusions). Three unanticipated adverse events (peripheral oedema, extremity pain and pseudo‐thrombocytopenia) from two surgical treatment events were reported that were potentially treatment‐related. No serious drug‐related adverse events (AEs) were observed, and no thrombotic events were reported in this study. This study supports the safety and efficacy of the FVIII/VWF concentrate Humate‐P® for the prevention of surgical haemorrhage in patients with VWD when administered in doses calculated in VWF:RCo units.Keywords
This publication has 25 references indexed in Scilit:
- High Plasma Levels of Factor VIII and the Risk of Recurrent Venous ThromboembolismNew England Journal of Medicine, 2000
- Hemophilia ANew England Journal of Medicine, 1994
- Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technologyAnnals of Hematology, 1991
- von Willebrand Factor and Platelet FunctionaAnnals of the New York Academy of Sciences, 1991
- Correction of prolonged bleeding time in von Willebrand's disease with Humate‐PTransfusion, 1990
- Absence of Anti-Human Immunodeficiency Virus Types 1 and 2 Seroconversion after the Treatment of Hemophilia A or von Willebrand's Disease with Pasteurized Factor VIII ConcentrateNew England Journal of Medicine, 1989
- Use of a High‐Purity Factor VIII Concentrate (Hemate P) in von Willebrand's Disease1Vox Sanguinis, 1989
- Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.Journal of Clinical Investigation, 1988
- The effect of thrombin on the complex between factor VIII and von Willebrand factorEuropean Journal of Biochemistry, 1987
- Factor VIII binds to von Willebrand factor via its Mr-80000 light chainEuropean Journal of Biochemistry, 1987